Quintrio
Home

PHARMACEUTICAL PREPARATIONS

iBio, Inc. Common Stock

IBIO

iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.

Last trade $0.7298
Day change +$0.0231 (+3.27%)
Day range $0.699 – $0.748
Volume 372,478
Market cap $50M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$50.02M
Price / earnings
—
Price / book
0.64×
Price / sales
46.53×
EV / sales
4.27×
EV / EBITDA
-0.2×

Profitability

Earnings per share
-$0.37
Return on assets
-29.21%
Return on equity
-32.95%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
9.48×
Quick ratio
9.48×
Cash ratio
5.3×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$27.59M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IBIO, quarterly periods
Line itemQ1 FY2027 Sep 30, 2026Q4 FY2026 Jun 30, 2026Q3 FY2026 Mar 31, 2026Q2 FY2026 Dec 31, 2025Q1 FY2026 Sep 30, 2025Q4 FY2025 Jun 30, 2025Q3 FY2025 Mar 31, 2025Q2 FY2025 Dec 31, 2024
Revenue$1.08M$0$0$0$100K$200K$0$200K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$1.08M$0$0$0$100K$200K$0$200K
Selling, general and administrative$2.76M-$2.18M$5.11M$0$2.5M$2.17M$2.97M$2.74M
Research and development$6.65M$8.56M$3.25M$0$3.55M$3.22M$1.91M$1.88M
Total operating expenses$9.41M$11.38M$8.37M$0$6.05M$5.4M$4.88M$4.62M
Operating income-$8.34M-$11.38M-$8.37M$0-$5.95M-$5.2M-$4.88M-$4.42M
Interest expense$0$46K-$22K$0-$34K-$44K-$54K-$57K
Income before taxes-$7.55M-$10.58M-$7.76M$0-$5.72M-$5.16M-$4.86M-$4.36M
Income taxes$0$0$0$0$0$0$0$0
Net income-$7.55M-$10.58M-$7.76M$0-$5.72M-$5.16M-$4.86M-$4.36M
Net income attributable to common shareholders-$7.55M-$10.58M-$7.76M$0-$5.72M-$5.16M-$4.86M-$4.36M
EBITDA-$8.19M-$6.23M-$8.21M$0-$5.82M-$5.07M-$4.75M-$4.29M
Basic earnings per share-$0.05-$0.04-$0.06$0.00-$0.11-$0.36-$0.49-$0.48
Diluted earnings per share-$0.05-$0.04-$0.06$0.00-$0.11-$0.36-$0.49-$0.48

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, a clinical-stage biotechnology company, announced fiscal year 2026 results marking its transition to clinical development with initiation of Phase 1 trials for IBIO-600, a long-acting anti-myostatin antibody. The company advanced IBIO-610 into IND-enabling studies showing fat-selective weight loss potential and completed successful financings totaling $126 million, extending cash runway into fiscal 2028. R&D expenses increased to $19.6 million from $8.3 million year-over-year, while the company held $88 million in cash and investments.

GlobeNewswire Inc.

iBio Announces $26 Million Private Placement

iBio, Inc. (NASDAQ: IBIO) announced a private placement financing of approximately $26 million led by Frazier Life Sciences. The company will use proceeds to advance preclinical cardiometabolic programs including IBIO-610 and IBIO-600, extending cash runway into calendar 2028. The offering is expected to close on January 13, 2026.

GlobeNewswire Inc.

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

iBio and AstralBio have developed a novel amylin receptor agonist antibody that significantly reduced acute food intake in a mouse model of obesity, comparable to a leading amylin peptide agonist. The findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 29, 20231-for-20reverse split
Oct 10, 20221-for-25reverse split
Jun 11, 20181-for-10reverse split